>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:
  • GBR +42.4%, (also files to delay its 10-K; additional time is required for the proper XBRL review process to be completed)
  • SHIP +20.1%, CONN +19.5%, XYL +2.1%, (increases its 2020 financial targets)
  • WWE +0.7%, (following late weakness from World Wrestling Business Update Call)
M&A news:
  • MSGN +11.3% (considering sale, according to NY Post)
Select metals/mining stocks trading higher:
  • SBGL +4.9%,FCX +3.2%, AU +3.2%, AG +3.1%, GFI +3%, GOLD+1.9%, HMY +1.9%, MTL +1.9%, AUY +1.4%
  • NEM +1.2%, GDX +1.1%, SLV +1.1%, ABX +1.1%, DRD +1%
Other news:
  • CYCC +39.9% (following 60%+ move higher on Monday)
  • PRTK +38.4% (Paratek Pharma reports 'positive' Phase 3 study of Omadacycline in community-acquired bacterial pneumonia)
  • BNTC +30.5% (announces that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications)
  • MLSS +25.9% (announces that it has been granted marketing clearance for its epidural and intra-articular instruments and disposables in Australia)
  • CTRV +10.1% (provides new insights into the mechanism of action of its hepatitis B virus (HBV)-optimized cyclophilin inhibitor CRV431)
  • QURE +10.1% (announces the online publication in Gene Therapy of data demonstrating widespread transduction in the CNS following direct injection of uniQure's AAV5 vector in a large animal model)
  • TXMD +6.5% (presents 'positive' safety and efficacy results from its Phase 3 data in two presentations for TX-001HR at ENDO)
  • PPHM +6.3% (announces the results of a new analysis of the Phase III SUNRISE trial of bavituximab)
  • RDHL +5.2% (confirms that the FDA has granted YELIVA (ABC294640) Orphan Drug designation)
  • GLPG +4.5% (announces the launch of 3 new Phase 2 Proof-of-Concept studies with filgotinibg)
  • ACHC +3.6% (will replace Joy Global in the S&P MidCap 400)
  • TEVA +2.4% (announces FDA approval of AUSTEDO (deutetrabenazine) tablets for the treatment of chorea associated with Huntington's disease )
  • QTM +1.6% (announces 1:8 reverse stock split effective following the close of trading on April 18 )
Analyst comments:
  • PSTG +4.1% (upgraded to Positive from Neutral at Susquehanna)
  • GWRE +3.6% (added to Conviction Buy List at Goldman)
  • BAX +1.6% (upgraded to Outperform from Mkt Perform at Leerink Partners)
  • ABUS +1.5% (upgraded to Buy at Chardan Capital Market)
  • MDLZ +1.5% (added to Conviction Buy List at Goldman)
  • CRUS +1.4% (upgraded to Overweight from Sector Weight at Pacific Crest)
  • CAT +1.3% (added to Conviction Buy List at Goldman)